What Avicenna.AI Announced About the AVI Platform Launch

Avicenna.AI said on 13 November 2025 that it launched AVI, a platform that delivers AI results into existing hospital systems. The company says it integrates directly with PACS and RIS without an extra viewer or a change to the workflow, runs fully automatically and is invisible to end users, and simplifies deployment for IT teams. It says the platform initially hosts the CINA portfolio, naming CINA-ICH, CINA-LVO and CINA-ASPECTS for neuro, CINA-VCF, CINA-VCF Quantix and CINA-CSpine for spine, and CINA-AD, CINA-PE and CINA-iPE for chest. Avicenna.AI says AVI supports workflows compliant with GDPR and HIPAA, de-identifying data before processing and re-identifying it on return, with encryption and access controls.

Why the Avicenna.AI AVI Platform Matters to Radiology IT Teams

The delivery layer is usually what kills imaging AI projects, not the algorithm, so a vendor shipping its own integration path instead of asking for another workstation is addressing the real obstacle. Listing all nine CINA products on one platform also means a department can add findings without another integration project, which is how this kind of purchase actually grows. Note what the platform is not: AVI is plumbing, and each CINA product carries its own clearance, so the platform does not extend any product's permitted use. The de-identification step is worth checking in detail, since it is the company's description of its own design rather than an audited control.

Where the Avicenna.AI Update Comes From

Avicenna.AI is the original record behind this update. It tells us what the company published. This brief adds the market context and the method we would use to test the development against other evidence.

Avicenna.AI original source.

How We Would Research the Avicenna.AI AVI Platform

The source gives us the starting point. This is how we would build the next layer of research around it.

  1. We would ask Avicenna.AI for the technical detail on where de-identification happens and where processing runs, since the claim is about data leaving the hospital.
  2. Then we would ask which PACS and RIS versions are supported in production rather than in principle.
  3. We would confirm each CINA product's own clearance separately, because a shared platform does not change what any one of them is cleared to report.